Table 2 Comparison of the improvement and non-improvement participant groups.
From: The utility of telemedicine in managing patients after COVID-19
Parameter | Improvement (n = 20) | Non-improvement (n = 10) | p value |
|---|---|---|---|
Saturation amplitude, %, median [IQR] | 7 [4–8] | 9 [7–11] | 0.03 |
Mean saturation, %, mean (SD) | 96 (1) | 94 (2) | 0.01 |
Minimum saturation, %, mean (SD) | 92 (4) | 89 (3) | 0.04 |
Hospitalization time, days, median [IQR] | 12 [7–14] | 30 [15–48] | 0.008 |
CT initial score, points, median [IQR] | 2/4 [1–3] | 3/4 [3–4] | 0.008 |
CT control score, points, median [IQR] | ¼ [1–2] | 4/4 [3–4] | 0.00002 |
FEV1 I, %, mean (SD) | 87.28 (13.67) | 59.89 (19.69) | 0.0003 |
FEV1 II, %, mean (SD) | 90.22 (9.39) | 69.1 (16.39) | 0.0002 |
FVC I, %, mean (SD) | 84.44 (14.01) | 56.11 (21.23) | 0.0003 |
FVC II, %, mean (SD) | 88.11 (9.87) | 62.7 (15.32) | 0.00001 |
FEV1/FVC I, mean (SD) | 82.1 (7.51) | 84.78 (6.69) | 0.38 |
FEV1/FVC II, mean (SD) | 80.7 (4.24.) | 86.26 (6.41) | 0.01 |
TLC I, %, mean (SD) | 89.56 (16.03) | 60.78 (29.2) | 0.003 |
TLC II, %, mean (SD) | 93 (13.38) | 75.6 (18.3) | 0.008 |
TL,CO I, %, mean (SD) | 80.11 (21.93) | 57.38 (35.42) | 0.05 |
TL,CO II, %, mean (SD) | 90 (19.31) | 68.9 (27.93) | 0.03 |
